Biotech Values

[DewDiligence]

Re: MNTA’s M254

In this case [CAR-T] the IVIG is being used for its immune reconstitution effects and presumably needs a full repertoire of Fab regions…

MNTA’s M254 is derived from ordinary IVIG that has been modified (recombinantly) to produce four sialylated Fc fragments for each IgG. M254 thus contains all of the Fab regions in the IVIG feedstock.

The potential reduction in cost of M254 compared to IVIG stems from its increased potency against inflammation (in animal models), enabling a much lower dose (perhaps as little as 10%) to have equivalent efficacy to IVIG. Whether M254’s increased potency against inflammation will allow a lower dose to be given for treating PID (including PID resulting from CAR-T treatment) is unclear.